In silico, in vitro, and in vivo models reveal EPHA2 as a target for decreasing inflammation and pathological endochondral ossification in osteoarthritis.
M. N. Ferrao Blanco, R. Lesage, N. Kops, N. Fahy, F. T. Bekedam, A. Chavli, Y. M. Bastiaansen-Jenniskens, L. Geris, M. G. Chambers, A. A. Pitsillides, R. Narcisi, G. J. V. M. van Osch
This study identifies EPHA2 as a therapeutic target for osteoarthritis by showing its inhibition reduces inflammation and pathological endochondral ossification in both in vitro and in vivo models.
bioRxiv · Jun 12, 2022Pharmacology & Toxicology